ResearcherShiraz UniversityActive in the last 2 years

Bahareh Hassani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3504-6207; OpenAlex author ID A5020114407. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2025.153080 ↗
Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. First author DOI 10.1016/j.bbcan.2024.189185 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Fatemeh Moosavi · 2 shared papers, 2024–2026 · strength 0.67
- Paper Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma. DOI 10.1016/j.bbrc.2025.153080 ↗
- Paper Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. DOI 10.1016/j.bbcan.2024.189185 ↗
Omidreza Firuzi · 2 shared papers, 2024–2026 · strength 0.67
- Paper Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma. DOI 10.1016/j.bbrc.2025.153080 ↗
- Paper Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. DOI 10.1016/j.bbcan.2024.189185 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.